Navigation Links
iBio, Inc. Prices $4.2 Million Public Offering

NEWARK, Del., April 23, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today the pricing of an underwritten public offering of 8,925,000 units at $0.48 per unit for gross proceeds of approximately $4,280,000. Each unit consists of one share of common stock and 0.40 of a warrant to purchase one share of common stock. The warrants will have an exercise price of $0.53 per share, will be exercisable from the date of issuance and will expire on the third anniversary of the issuance date. The offering is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended.

(Logo: )

iBio plans to use proceeds of the offering for working capital, including further development of iBio's product candidates and proprietary technology, business development and for other general corporate purposes. 

Roth Capital Partners is acting as sole manager for the offering. iBio expects to close the transaction, subject to customary conditions, on or about April 26, 2013.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from:

Roth Capital Partners
By Email:
By Fax: 949.720.7227
Or by mail:
888 San Clemente Drive
Newport Beach, CA 92660
ATTN: Equity Capital Markets

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
2. iBio, Inc. Prices $10 Million Public Offering
3. iBio, Inc. and GE Healthcare form new global alliance
4. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
5. iBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards
6. iBio, Inc. Announces Proposed Public Offering
7. BioMed Realty, L.P. Prices $250 Million Offering Of 4.25% Senior Unsecured Notes Due 2022
8. Sequenom Prices Offering of $110 Million of its 5.00% Convertible Senior Notes Due 2017
9. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
10. BioMed Realty Trust Prices Public Offering Of 12,700,000 Shares Of Common Stock
11. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
Post Your Comments:
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving ... marijuana products targeting the needs of consumers who are incorporating medical marijuana into ... in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
(Date:10/7/2017)... 2017  The 2017 Nobel Prize in Chemistry ... Dubochet, Joachim Frank and Richard ... microscopy (cryo-EM) have helped to broaden the ... community. The winners worked with systems manufactured by ... highly resolved, three-dimensional images of protein structures that ...
(Date:10/6/2017)... Washington, D.C. (PRWEB) , ... October 06, 2017 ... ... Cure) will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive ... INSIGhT Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):